Brazil’s largest drugstore chains are experiencing a significant, sustained surge in sales driven by the explosion in demand for GLP-1 class medications, the injectable treatments originally developed for diabetes but now widely used for weight loss. The momentum from these powerful prescription drugs is expanding the entire pharmaceutical retail market in Brazil, with sales to consumers growing an estimated 9.1% year-on-year in July 2026 alone.